Navigation Links
Previous Claims of siRNA Therapeutic Effects Called into Question by Report in 'Human Gene Therapy'
Date:9/2/2008

ing a mouse model of influenza, the authors demonstrated that the anti-viral activity of siRNA is mainly due to non-specific stimulation of the immune system rather than to a targeted attack on the disease-causing virus.

"siRNA holds tremendous potential as a research tool, however its clinical development is still in its infancy. The study by Robbins et al. points out a very important issue regarding non-specific effects that should be considered when designing and evaluating siRNA strategies," says James M. Wilson, MD, PhD, Editor-in-Chief, and Head of the Gene Therapy Program, Division of Medical Genetics, University of Pennsylvania School of Medicine, in Philadelphia.

'Human Gene Therapy,' the Official Journal of the European Society of Gene and Cell Therapy (http://www.esgct.org), the British Society for Gene Therapy (http://www.bsgt.org), and the French Society of Cell and Gene Therapy (http://www.sftcg.fr), is an authoritative peer-reviewed journal published monthly in print and online that presents reports on the transfer and expression of genes in mammals, including humans. Related topics include improvements in vector development, delivery systems, and animal models, particularly in the areas of cancer, heart disease, viral disease, genetic disease, and neurological disease, as well as ethical, legal, and regulatory issues related to the gene transfer in humans. Tables of contents and a free sample issue may be viewed online at http://www.liebertpub.com

Mary Ann Liebert, Inc (http://www.liebertpub.com) is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including 'Tissu
'/>"/>

SOURCE Mary Ann Liebert, Inc
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. European Unions CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
2. Risks Associated With Face Transplants May Be Lower Than Previously Thought, ASPS Journal Review Suggests
3. Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy
4. Phase II Study of Zevalin(R) Consolidation Following Fludarabine and Mitoxantrone Chemotherapy Results in 100 Percent Complete Remission Rate and 89 Percent Three-Year Progression Free Survival in Patients with Previously Untreated Non-Follicular Indolent
5. CASTLE Study Showed Similar Efficacy Between Once-Daily REYATAZ(R) (atazanavir sulfate)/ritonavir and Twice-Daily lopinavir/ritonavir at 48 Weeks in Previously Untreated HIV-Infected Adult Patients
6. Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
7. Karmanos Doctors Urge Increased Screening for Previously Treated Lung Cancer Patients, Especially Young Women
8. ACTEMRA(R) (tocilizumab) Significantly Reduces Rheumatoid Arthritis Signs and Symptoms Regardless of Previous Therapy in Two New Global Studies
9. Results Published in the Journal Cancer Demonstrate that Oral Talactoferrin Alfa is Active as Monotherapy in Previously Treated Patients with Metastatic Renal Cell Carcinoma
10. Pressure Cycling Technology (PCT) Results in a Higher Yield of Proteins and in the Extraction of Proteins Not Previously Identified in Cancer, Stroke, and IVF Studies
11. Bradmer reports progression free survival data from previous Phase II glioblastoma multiforme trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2008)...e-USNewswire/ -- Abnormalities in auditory and lan... autism spectrum disorder by using magnetoencephal...y at the annual meeting of the Radiological Societ...we can record the tiny magnetic fields associated ...rts, Ph.D., vice chair of research in the Departme...
(Date:11/28/2008)...ewswire-FirstCall/ -- Eli Lilly and Company,(NYSE...Application (sNDA) from,the U.S. Food and Drug Ad...),for the management of chronic pain. Lilly plans... 2009, adding data from a recently completed posit...nee. , The decision does not affect duloxet...
(Date:11/26/2008)... Children whose eyes are... increased risk of developing mental illness by ea...inic study published this month in Pediatrics , th...atrics. , , The retrospective study examine...mus (misaligned eyes) and compared them with recor...
(Date:11/26/2008)...ects , , FRANKLIN, Mass., Nov. 26 /PRNewswi...ard: PLCSF) announced today that it has received f...ation (FDA) for its U.S. pivotal trial to study th...(TM) and associated therapy in the prevention of ... FDA also approved PLC,s request to expand their i...
Breaking Medicine Technology:Brain Waves Show Sound Processing Abnormalities in Autistic Children 2Brain Waves Show Sound Processing Abnormalities in Autistic Children 3Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 2Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 3Lilly Withdraws Application for Additional U.S. Indication for Cymbalta(R) for Chronic Pain 4Eye Divergence in Children Triples Risk of Mental Illness 2PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 2PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 3PLC Systems Receives Full FDA Approval for Pivotal Study of RenalGuard(TM) in The U.S. 4Possible biological explanation for C Section linked allergies and asthma found 19976 1Possible biological explanation for C Section linked allergies and asthma found 19976 2Crdentia Announces 2008 First Quarter Results 19972 1Crdentia Announces 2008 First Quarter Results 19972 2Crdentia Announces 2008 First Quarter Results 19972 3Crdentia Announces 2008 First Quarter Results 19972 4Crdentia Announces 2008 First Quarter Results 19972 5Crdentia Announces 2008 First Quarter Results 19972 6Crdentia Announces 2008 First Quarter Results 19972 7FDA Accepts Zingo 28TM 29 Supplemental New Drug Application to Reduce Pain Associated With Peripheral Needle Insertion Procedures in Adults 5547 1FDA Accepts Zingo 28TM 29 Supplemental New Drug Application to Reduce Pain Associated With Peripheral Needle Insertion Procedures in Adults 5547 2FDA Accepts Zingo 28TM 29 Supplemental New Drug Application to Reduce Pain Associated With Peripheral Needle Insertion Procedures in Adults 5547 3FDA Accepts Zingo 28TM 29 Supplemental New Drug Application to Reduce Pain Associated With Peripheral Needle Insertion Procedures in Adults 5547 4Iraq war service 3A A risk factor for bronchiolitis 3F 19967 1Iraq war service 3A A risk factor for bronchiolitis 3F 19967 2
..., FL -- (MARKET WIRE) -- July 06, 2007 -- DOR BioP...://studio.financialcontent.com/Engine?Account=iwir...p://studio.financialcontent.com/Engine?Account=iwi...R" or the "Company") announced today that the Euro...7 B1, with claims related to,oral vaccination usin...
...ublished in The Lancet on TMC125, an Investigation... /PRNewswire/ -- Data from two,ongoing Phase 3 stu... HIV-1 adult patients with documented non-nucleosi...tease inhibitor (PI),resistance reached an undetec...ndetectable level < 50 HIV-1 RNA copies/mL) with,T...
Other Medicine Technology:DOR BioPharma Announces Issuance of European Patent for Its Oral,Multivalent Botulinum Toxin Vaccine BT-VACC 2DOR BioPharma Announces Issuance of European Patent for Its Oral,Multivalent Botulinum Toxin Vaccine BT-VACC 3DOR BioPharma Announces Issuance of European Patent for Its Oral,Multivalent Botulinum Toxin Vaccine BT-VACC 4DOR BioPharma Announces Issuance of European Patent for Its Oral,Multivalent Botulinum Toxin Vaccine BT-VACC 5DOR BioPharma Announces Issuance of European Patent for Its Oral,Multivalent Botulinum Toxin Vaccine BT-VACC 6TMC125 Showed Significant Virologic Response at Week 24 in,Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3,Trials 2TMC125 Showed Significant Virologic Response at Week 24 in,Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3,Trials 3TMC125 Showed Significant Virologic Response at Week 24 in,Treatment-Experienced HIV Patients With NNRTI Resistance in Phase 3,Trials 4
(Date:12/1/2008)... 1 This December, Anthem Blue,Cro...he Anthem Blue Cross,HealthFair Bus travels the s...,on Monday, December 1 from the Anthem offices in ...n a multi-city tour to include Los Angeles, Ventur...isco (see detailed schedule,below). , (Pho...
(Date:12/1/2008)...PRNewswire/ -- Question. What would happen if,we ...lding exercise? The,fitness world would certainly...rship fees would have to close. 2. Phony exercise ...t. 3. We would never have to spend another dime on...,s take-home pay is now estimated at 35 billion,d...
(Date:12/1/2008)...D Global Telemedicine, Inc. deploys telemedicine d...t program. 17 school sites in Sevier County, Tenne..., North Chelmsford, MA (PR...dicine & Cherokee Health Systems collaborated ...s in Sevier County, Tennessee. In addition to thi...
(Date:12/1/2008)...stage breast cancer who have undergone breast augm...l-breast radiation treatment called brachytherapy,...l meeting of the Radiological Society of North Ame...ave better cosmetic outcomes and avoid the risk of...ndergo whole-breast radiation therapy. , "We are...
Breaking Medicine News(10 mins):Health News:Anthem Blue Cross Gives the Gift of Health to California 2Health News:Anthem Blue Cross Gives the Gift of Health to California 3Health News:Push-Ups: 'It's Horizontal Jogging' 2Health News:Telemedicine Becoming More Relevant to Children's Health Within School Systems. 2Health News:Telemedicine Becoming More Relevant to Children's Health Within School Systems. 3Health News:Breast cancer treatment offers better outcome to women with implants 2
...2006 issue of General Dentistry, the AGD’s clinica...especially that of the tongue is harmful and shoul...e, the report describes the condition of a young g...was massive scar tissue formation around the area ...
... milk substitute, and a highly vulnerable commodit...ealth concerns determine what goes into formula mi.../ The Codex Alimentarius Commission, part of bot...of the United Nations and the World Health Organis...
...ched a $38 million project along with major region...u threat in Asia and the Pacific. // The Manila-b...e resources urgently needed to help control and re...us, and to increase the region's preparedness for ...
...ons (ASPS) reports say that plastic surgery was pe... The ethnic community opts for this surgery than ...nce their appearance or minimize the signs of agin...nd more people opted for it in the year 2005 with ...
Other Medicine News:
...a national reference laboratory and a worldwide le...ment. ARUP offers an extensive test menu of highly...anatomic pathology. Owned by the University of Uta...lf of the nation's university teaching hospitals a...
...a national reference laboratory and a worldwide le...ment. ARUP offers an extensive test menu of highly...anatomic pathology. Owned by the University of Uta...lf of the nation's university teaching hospitals a...
...a national reference laboratory and a worldwide le...ment. ARUP offers an extensive test menu of highly...anatomic pathology. Owned by the University of Uta...lf of the nation's university teaching hospitals a...
...a national reference laboratory and a worldwide le...ment. ARUP offers an extensive test menu of highly...anatomic pathology. Owned by the University of Uta...lf of the nation's university teaching hospitals a...
Medicine Products: